Caidya, a US-based global provider of clinical trial solutions, announced on Monday that it has named Barbara Lopez Kunz as its new chief executive officer, effective 1 September 2024.
In the new role, Kunz is to concentrate on improving the company's position as a global leader in clinical research, emphasising the importance of patient-centred trials and building personalised, fit-for-purpose solutions.
Kunz is a member of the Caidya board of directors. She has a range of experience and has worked in various leadership capacities across the healthcare and life sciences sectors. She has more than 15 years of C-suite experience and a proven track record in driving strategic partnerships and digital transformation. She has held significant P&L responsibilities at major companies including Thermo Fisher Scientific, DuPont, and ICI (now AstraZeneca), as well as at non-profits like Battelle and DIA.
Expanse Medical names new chief executive officer and FlowPhysix board member
DELFI Diagnostics names new chief financial officer
Qaelon Medical names new chief executive officer
BioMarin Pharmaceutical names new executive vice president, chief research & development officer